However, OTUD1 conferred erlotinib susceptibility in NSCLC by repressing the nuclear translocation of YAP1 (112).OTUD5 knockdown also potentiated resistance to doxorubicin and cisplatin in NSCLC cells (113). This evidence concerns the gene YAP1 and non-small cell lung carcinoma.